Media stories about AtriCure (NASDAQ:ATRC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 46.2382038593769 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Several research firms have weighed in on ATRC. ValuEngine upgraded AtriCure from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Leerink Swann restated an “outperform” rating and issued a $26.00 price target on shares of AtriCure in a research report on Friday, June 16th. BidaskClub lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 price objective (up from $25.00) on shares of AtriCure in a research note on Friday, July 28th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $25.00 price objective on shares of AtriCure in a research note on Sunday, July 30th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. AtriCure has a consensus rating of “Hold” and an average target price of $25.00.

Shares of AtriCure (ATRC) opened at 22.37 on Friday. The firm has a 50-day moving average price of $21.90 and a 200-day moving average price of $21.44. The company’s market capitalization is $768.05 million. AtriCure has a one year low of $14.78 and a one year high of $25.18.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 27th. The medical device company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.05. The company had revenue of $45.23 million during the quarter, compared to analysts’ expectations of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. AtriCure’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.26) EPS. Equities analysts forecast that AtriCure will post ($0.95) earnings per share for the current year.

In related news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total transaction of $224,000.00. Following the completion of the sale, the director now directly owns 29,967 shares in the company, valued at approximately $671,260.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 10.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.